A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants

NCT06555081 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

DRUG: Ruxolitinib IR
DRUG: Ruxolitinib XR

Sponsor

Incyte Corporation